Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew E Aplin

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
The Journal of Investigative Dermatology|November 12, 2010
Paying "particle" attention to novel melanoma treatment strategiesMichele B Weiss, Andrew E Aplin
Pharmacology & Therapeutics|May 5, 2022
The future of targeted kinase inhibitors in melanomaSigne Caksa, Usman Baqai, Andrew E Aplin
The Journal of Investigative Dermatology|October 11, 2013
Resistance to RAF inhibitors revisitedEdward Hartsough, Yongping Shao, Andrew E Aplin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2018
Playing the Melanoma EndgameJessica L F Teh, Andrew E Aplin
Disease Models & Mechanisms|February 11, 2022
RAS-mediated tumor stress adaptation and the targeting opportunities it presentsAlexandra Redding, Andrew E Aplin, Elda Grabocka
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2018
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune MicroenvironmentJessica L F Teh, Andrew E Aplin
The Journal of Investigative Dermatology|May 20, 2011
Mechanisms of resistance to RAF inhibitors in melanomaAndrew E Aplin, Fred M Kaplan, Yongping Shao
Cancer Research|January 15, 2021
Roles of the BAP1 Tumor Suppressor in Cell MetabolismAnna Han, Timothy J Purwin, Andrew E Aplin
Molecular Cancer Research : MCR|October 20, 2006
Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancerCeshi Chen, Arun K Seth, Andrew E Aplin
Trends in Cancer|June 15, 2021
Metabolic Alterations and Therapeutic Opportunities in Rare Forms of MelanomaAnna Han, Zachary T Schug, Andrew E Aplin
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
The Journal of Investigative Dermatology|November 12, 2010
Paying "particle" attention to novel melanoma treatment strategiesMichele B Weiss, Andrew E Aplin
Pharmacology & Therapeutics|May 5, 2022
The future of targeted kinase inhibitors in melanomaSigne Caksa, Usman Baqai, Andrew E Aplin
The Journal of Investigative Dermatology|October 11, 2013
Resistance to RAF inhibitors revisitedEdward Hartsough, Yongping Shao, Andrew E Aplin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2018
Playing the Melanoma EndgameJessica L F Teh, Andrew E Aplin
Disease Models & Mechanisms|February 11, 2022
RAS-mediated tumor stress adaptation and the targeting opportunities it presentsAlexandra Redding, Andrew E Aplin, Elda Grabocka
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2018
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune MicroenvironmentJessica L F Teh, Andrew E Aplin
The Journal of Investigative Dermatology|May 20, 2011
Mechanisms of resistance to RAF inhibitors in melanomaAndrew E Aplin, Fred M Kaplan, Yongping Shao
Cancer Research|January 15, 2021
Roles of the BAP1 Tumor Suppressor in Cell MetabolismAnna Han, Timothy J Purwin, Andrew E Aplin
Molecular Cancer Research : MCR|October 20, 2006
Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancerCeshi Chen, Arun K Seth, Andrew E Aplin
Trends in Cancer|June 15, 2021
Metabolic Alterations and Therapeutic Opportunities in Rare Forms of MelanomaAnna Han, Zachary T Schug, Andrew E Aplin
Pageof 16